Follow us on Twitter
twitter icon@FreshPatents

Dimethyl patents

Bulk PDF Downloads

This page is updated frequently with new Dimethyl-related patent applications.

 Method and kit for detection of microorganism patent thumbnailMethod and kit for detection of microorganism
3) a primer or primers for amplifying a target region of the dna or rna of the microorganism to be detected by a nucleic acid amplification method. The agent for suppressing a nucleic acid amplification inhibitory substance is one or more selected from albumin, dextran, t4 gene 32 protein, acetamide, betaine, dimethyl sulfoxide, formamide, glycerol, polyethylene glycol, soybean trypsin inhibitor, α2-macroglobulin, tetramethylammonium chloride, lysozyme, phosphorylase and lactate dehydrogenase..

 Antithrombotic material patent thumbnailAntithrombotic material
An antithrombogenic material includes a coating material containing: a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; and a base material whose surface is coated with the coating material; wherein the polymer is covalently bound to the base material; and an abundance ratio of nitrogen atoms to an abundance of total atoms as measured by x-ray photoelectron spectroscopy (xps) on a surface of the base material is 6.0 to 12.0 atomic percent.. .
Toray Industries, Inc.

 Topical medications for bruises and burns patent thumbnailTopical medications for bruises and burns
Topical medications to treat the physical effects of bruises and burns. For bruises, the topical medication preferably includes therapeutically effective amounts of vasoconstrictor, such as phenylephrine hcl usp, an anti-inflammatory, such as arica, and compounding agents.
Meridian Research And Development, Inc.

 Composition of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione patent thumbnailComposition of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
The present invention relates to a composition of benzoxazinone (i) comprising the benzoxazinone (i) in form of particles, wherein at most 50% per volume of the particles have a diameter below 3 μm.. .
Basf Se

 Fluorinated alkali ion electrolytes with urethane groups patent thumbnailFluorinated alkali ion electrolytes with urethane groups
Perfluoropolyether electrolytes terminated with polar substituents such as dimethylurethanes show enhanced ionic conductivities when formulated with lithium bis(trifluoromethane)sulfonimide, making them useful as electrolytes for lithium cells.. .
Seeo, Inc

 Organic metal compound, organic light-emitting device, and lighting device employing the same patent thumbnailOrganic metal compound, organic light-emitting device, and lighting device employing the same
Wherein each r1 is independent and can be hydrogen, halogen, c1-10 alkyl group, c5-10 cycloalkyl group, or c5-12 aryl group; r2 is trialkyl silyl group; and l is a picolinic acid ligand, a 2-(imidazol-2-yl) pyridine ligand, a 2-(4,5-dimethyl-imidazol-2-yl) pyridine ligand, a 3-(trifluoromethyl)-5-(pyridine-2-yl)-1,2,4-triazolate ligand, or a 3-(isobutyl)-5-(pyridine-2-yl)-1,2,4-triazolate ligand.. .

 Selectively removing titanium nitride hard mask and etch residue removal patent thumbnailSelectively removing titanium nitride hard mask and etch residue removal
Formulations for stripping titanium nitride hard mask and removing titanium nitride etch residue comprise an amine salt buffer, a non-ambient oxidizer, and the remaining being liquid carrier includes water and non-water liquid carrier selected from the group consisting of dimethyl sulfone, lactic acid, glycol, and a polar aprotic solvent including but not limited to sulfolanes, sulfoxides, nitriles, formamides and pyrrolidones. The formulations have a ph <4, preferably <3, more preferably <2.5.
Air Products And Chemicals, Inc.

 Anilino podophyllin derivative having antitumor activity,  preparation thereof, and use thereof patent thumbnailAnilino podophyllin derivative having antitumor activity, preparation thereof, and use thereof
The present invention discloses an anilino-substituted podophyllin derivative having antitumor activity, method for preparation thereof, and use thereof. By means of anilino reactions, the present invention introduces 4-chloro-3-methylaniline, 3-fluoro-4-methoxyaniline, 4,4′-diaminodiphenylmethane, o-anisidine, 4-chloro-2-aminoanisole, anthranilonitrile, 2,6-dichloro-4-aminophenol, n,n-dimethylamino meta-aniline, 2-ethyl-5-nitroaniline, 2 2′-diaminodiphenylsulfide, or 2-aminobenzotrifluoride into position 4 of the active c-ring of podophyllotoxin or 4′-demethylepipodophyllotoxin to obtain the aniline-substituted podophyllotoxin derivative shown in formula (v); by means of multi-pathway and multi-target effects on tumor cells, said derivative has significantly increased antitumor activity, and can be prepared as an antineoplastic drug and applied in clinical antitumor therapy..
Hubei University Of Technology

 The crystalline forms of temozolomide and the  preparing same patent thumbnailThe crystalline forms of temozolomide and the preparing same
Provided in the present invention are a new method for preparing the crystalline forms of temozolomide and three types of crystalline form of temozolomide by the method. Said method comprises the following steps: a temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester..
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form patent thumbnail1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate.
Lek Pharmaceuticals D.d.

Process for alkylation using ionic liquid catalysts

Alkylation processes are described. The processes utilize ionic liquid catalysts having a kinematic viscosity range of about 50 cst to about 100 cst at 25° c.
Uop Llc

Combination therapy for treating disorders associated with excess cortisol production

Methods are provided for treatment of disorders associated with excess cortisol production, including, but not limited to, treatment of cushing's syndrome. Such methods involve administration of a therapeutically effective amount of a combination of: (a) an inhibitor of cyp11b1; and (b) acat1 inhibitor n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethyl-lamino)phenyl)cyclopentyl)-methyl)urea or a salt thereof; or (a) an inhibitor of cyp11b1; (b) an inhibitor of cyp11b2; and (c) acat1 inhibitor n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethyl-lamino)phenyl)cyclopentyl)-methyl)urea or a salt thereof..
Millendo Therapeutics, Inc.

Delayed curing silane-based curable resin system

Method involving consolidation compositions comprising an aqueous-based fluid, a silane-based resin, a silane-based amine curing agent, and a delaying agent. The silane-based resin is an epoxy-functionalized alkoxysilane selected from the group consisting of: (3 glycidoxypropyl)trimethoxysilane, (3 glycidoxypropyl)triethoxysilane, 5,6 epoxyhexyltriethoxysilane, (3 glycidoxypropyl)methyldiethoxysilane, (3 glycidoxypropyl)methyldimethoxysilane, and (3 glycidoxypropyl)dimethylethoxysilane.
Halliburton Energy Services, Inc.

Compound for inhibiting the growth and proliferation of human liver cancer cells and synthesizing it

The compound “2-((4-nitrophenyl)amino)-6,7,8,9-tetrahydro-3h-cyclohepta[4,5]thieno-[2,3-d]pyrimidin-4(5h)-one” and method of synthesizing it, wherein the compound is effective to inhibit the growth and proliferation of human liver cancer cells hepg2. The compound has an inhibitory concentration value (ic50) of 0.7 μg, compared to reference medication doxorubicin that has an (ic50) value of 1.2 μg.

(3r) epimer of octahydro-7,7-dimethyl-8-methylene 1h-3a, 6-methanoazulen-3-yl acetate, composition, synthesis process and use of said epimer

The first subject matter of the invention is the (3r) epimer of octahydro-7,7-dimethyl-8-methylene-1h-3a, 6-methanoazulen-3-yl acetate [(octahydro-7,7-dimethyl-8-methylene-[3r,3ar,6r,8ar]-1h-3a,6-methanoazulen-3-yl acetate) or (r)-norzizaenylacetate] of formula i (i). The subject matter of the invention is also compositions comprising (r)norzizaenyl acetate and also a novel synthesis process and the use of said ester..
Centre National De La Recherche Scientifique (cnrs)

Preparation of functionalised carbon nanomaterials

The invention provides for a method of preparing a covalently functionalised carbon nanomaterial, comprising the steps of (i) treating a carbon material with a reducing agent comprising an alkali metal m in the presence of a solvent s to form a reduced-carbon material solution; and (ii) treating the resulting reduced-carbon material solution with a functionalising reagent to form a covalently functionalised carbon nanomaterial, wherein (a) the concentration of alkali metal [m] in step (i) is between 0.003 mol/l and 0.05 mol/l, and (b) the ratio of carbon material to alkali metal (c/m) in solution in step (i) is at least 2:1. A method of preparing a covalently functionalised carbon nanomaterial using n,n-dimethylacetamide as a solvent is also provided..
Imperial Innovations Limited

Therapeutic compositions including modulators of deltapkc and/or epsilonpkc, and uses thereof

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of peptide modulators of pkc isozymes (“pmpkcs”), and/or naturally or artificially occurring derivatives, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to pmpkcs and uses of the same.

Fumigant compositions and methods

Fumigant compositions including hexafluoropropene or 1,1,3,3,3-pentafluoropropene, and methods of making such compositions, are provided herein. The fumigant compositions may be suitable for use as soil fumigant compositions and structural fumigant compositions against a variety of undesirable species such as weeds, nematodes, pathogens, animals and insects.
Honeywell International Inc.

One-photon and/or two-photon fluorescent probe for sensing hydrogen sulfide, imaging hydrogen sulfide using same, and manufacturing method thereof

The present invention relates to a one-photon and/or two-photon fluorescent probe for selectively detecting hydrogen sulfide in the human body using a compound including an α,β-unsaturated carbonyl group and an acedan (2-acyl-6-dimethyl-amino-naphthalene) fluorescent material; to an imaging method of hydrogen sulfide in cells using the same; and to a manufacturing method of the fluorescent probe. More specifically, in the fluorescent probe of the present invention, the α,β-unsaturated carbonyl group of the compound selectively binds to hydrogen sulfide, inducing an increase in fluorescence of the acedan fluorescent material.
Postech Academy-industry Foundation

Screening selected amino-lipid-containing compositions

The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.. .
Tekmira Pharmaceuticals Corporation

Polycyclohexylenedimethylene terephthalate resin composition

The present invention relates to a polycyclohexylenedimethylene terephthalate resin composition having improved reflectivity, heat resistance, and yellowing resistance. The resin composition according to one embodiment of the present invention includes 40 to 95 wt % of polycyclohexylenedimethylene terephthalate resin; 1 to 50 wt % of a white pigment; and 1 to 50 wt % of a filler, and the amount of germanium (ge) atoms remaining in the resin is 30 to 1,000 ppm based on the weight of the resin..
Sk Chemicals Co., Ltd.

Process for the preparation of n-iodoamides

The present invention provides new stable crystalline n-iodoamides -1-iodo-3,5,5-trimethylhydantoin (1-itmh) and 3-iodo-4,4-dimethyl-2-oxazolidinone (idmo). The present invention further provides a process for the preparation of organic iodides using n-iodoamides of this invention and recovery of the amide co-products from waste water..
Technion Research & Development Foundation Limited

Preparation dexmedetomidine intermediate

The present invention discloses a preparation method of 2,3-dimethyl phenyl-1-trityl-imidazole-4-ketone. In accordance with this method, imidazole-4-ethyl formate is used as a raw material; ethyl formate is used for amino protection, 1-trityl-1h-imidazole-4-formic acid is obtained after basic hydrolysis; 1-trityl-1h-imidazole-4-formic acid and n,o-dimethylhydroxylamine hydrochloride are subjected to condensation so as to obtain n-methoxyl-n-methyl-1-trityl-1h-imidazole-4-formamide; and n-methoxyl-n-methyl-1-trityl-1h-imidazole-4-formamide and a grignard reagent prepared by the reaction of 2,3-dimethylbromobenzene with magnesium are subjected to a grignard reaction, and then the target product 2,3-dimethyl phenyl-1-trityl-1h-imidazole-4-ketone is obtained.
Tianjin Weijie Pharmaceutical Co., Ltd

Vapor deposition of metal oxides, silicates and phosphates, and silicon dioxide

Metal silicates or phosphates are deposited on a heated substrate by the reaction of vapors of alkoxysilanols or alkylphosphates along with reactive metal amides, alkyls or alkoxides. For example, vapors of tris(tert-butoxy)silanol react with vapors of tetrakis(ethylmethylamido) hafnium to deposit hafnium silicate on surfaces heated to 300° c.
President And Fellows Of Harvard College

Biocompatible and bioabsorbable derivatized chitosan compositions

The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (edc) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of n-deacetylation (dda) of between about 15% and 40%.
Hemcon Medical Technologies, Inc.

Method for preparing ibrutinib

Provided is a method for preparing ibrutibin (i), and steps of preparing same comprise: 4-benzyloxybenzoyl chloride (ii) is used as a raw material, condensation and methoxidation reactions occur among 4-benzyloxybenzoyl chloride (ii), malononitrile, and dimethyl sulfate to generate 4-benzyloxyphenyl(methoxy)vinylidenedicyanomethane (iii), pyrazole cyclization occurs between the intermediate (iii) and 1-(3r-hydrazino-1-piperidino)-2-propylene-1-ketone (iv) to acquire 1-[(3r)-[3-(4-benzyloxyphenyl)-4-nitrile-5 -amino-1h-pyrazole]-1-piperidino]-2 propylene-1-ketone (v), and pyrimidine cyclization occurs between an intermediate (v) and a cyclizing agent to prepare ibrutinib (i). In the preparation method, the raw material is readily available, and the process is simple, economical, environmentally friendly, and is suitable for industrial production..
Suzhou Miracpharma Technology Co., Ltd.

Novel intermediate of tapentadol

The present invention relates to novel carbamate intermediate of formula (ii), process for its preparation and process for its conversion into 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol, tapentadol and its pharmaceutically acceptable salts.. .
Sun Pharma Advanced Research Company

Structure directing agent for improved synthesis of zeolites

The present invention relates to structure directing agents for synthesis of crystalline materials generally known as zeolites, by use of an enhanced content of the trans isomer of a 3,5-dimethyl-n,n-dimethylpiperidinium cation together with the conventional oxides used to form zeolites.. .
Sachem, Inc.

Partial skull replacements capable of monitoring in real time and delivering substances into brain tissue, and uses thereof

The present invention relates to a partial skull replacement consisting of polydimethylsiloxane (pdms) and a method of monitoring biological tissues within a skull using the partial skull replacement. The method of monitoring using the partial skull replacement of the present invention has a minimal influence on intracranial pressure and cerebrospinal fluid flow as compared to a conventional cranial window technique using glass, and, by way of visualizing biological tissues within a skull with enhanced clarity, is expected to be usefully employed as a method of monitoring biological tissues within the skull..
Institute For Basic Science

Thermoplastic article with active agent

An extruded water-soluble article made is from a homogeneous material that includes a water-soluble polymer having an extrusion temperature of 50 to 150° c. The article further includes between 0.1% to 50% by weight of an active agent.
Kimberly-clark Worldwide, Inc.

Compositions and therapeutic methods for the treatment of complement-associated diseases

The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of formula i or formula ii, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3h)-one or a pharmaceutically acceptable salt thereof.. .
Resverlogix Corp.


The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 2-[(5-chloro-2-{[3-methyl-1-(1-methylethyl)-1h-pyrazol-5-yl]amino}-4-pyridinyl)amino]-n-(methyloxy)benzamide, or a pharmaceutically acceptable salt thereof, and n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof..
Glaxosmithkline Llc

Method and device for indicating moisture based on bis(glyoxime)-transition metal complexes

Compositions that include bis(glyoxime)-transition metal complexes bound to metal oxide solid supports are provided. In some embodiments the compositions include nickel dimethylglyoxime and the metal oxide supports can be alumina or silica.
3m Innovative Properties Company

Standard analyte generator

The invention describes the process by which a standard mixture of organic compounds are spiked and retained onto a composite sorbent matrix for the controlled generation of a standard in fluid above the spiked matrix either in gas (headspace) or aqueous phase which is contained in portable vials. The novelty of the aforementioned composite matrix stems from the combination of an immobilizing liquid phase such as silicone oil or a polyacrylonitrile solution, and solid, porous particles such as polystyrene-co-divinylbenzene (ps-dvb) or hydrophilic/lipophilic balance (hlb) particles to strongly retain the spiked standards facilitating high capacity which translates into prolonged use as a source of calibrant.

Crystalline solvate forms of cabazitaxel

The present invention relates to new crystalline forms of cabazitaxel of formula (i). Specifically, the present invention provides four new crystalline solvate forms of cabazitaxel, designated as form s2 (solvate with 2-methyltetrahydrofuran), form s4 (solvate with tent-butyl acetate), form s5 (solvate with dimethylcarbonate) and form s6 (solvate with n-methyl-2-pyrrolidinone).
Indena S.p.a.

Synthesis of hyperbranched amphiphilic polyester and theranostic nanoparticles thereof

A method of making a hyperbranched amphiphilic polyester compound includes drying under vacuum a mixture of 2-(4-hydroxybutyl)-malonic acid and p-toluene sulphonic acid as catalyst. The vacuum is then released with a dry inert gas after drying.
University Of Central Florida Research Foundation, Inc.

Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Pharmaceutical compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof adapted so that release does not take place in the stomach is provided.. .
H. Lundbeck A/s

Led encapsulant

(i) a linear polymer including a dimethylsiloxane group which has a vinyl end substituent and/or a linear polymer including a methylphenylsiloxane group which has a vinyl end substituent; and (ii) at least one vinyl-based resin selected from the group consisting of a vinyl-based vimq resin. An led package comprising the encapsulant is also disclosed..

Method for preparing ionic liquid having carboxylic acid anion using microreactor

The present invention relates to a method for preparing an ionic liquid having a carboxylic acid anion using a microreactor. More specifically, the present invention relates to a method for preparing, with high efficiency, an ionic liquid having a carboxylic acid anion as shown in fig.
Chemtech Research Incorporation

Method for preparing heterogenetic corneal material

Disclosed is a method for preparing a heterogenous corneal material, wherein during the whole preparation process, different concentrations of glycerol are used to achieve that the heterogenous corneal graft has the transparent, properties of no viruses and cells; resistance to degradation and immunogenicity of collagen can be further reduced by collagen cross-linking; and under the whole eye saving, cross-linkers 1-(3-dimethylaminopropyl)-3-ethylcarbodi imide (edc) and n-hydroxy sulfosuccinimide (nhs) are used for cross-linking, thus enabling the form thereof to be closer to that of a fresh cornea and improving biomechanical properties thereof. The method can prepare a heterogenous corneal material with a high transparency, a low immunogenicity and a good bioactivity and biocompatibility, and can maintain that the three-dimensional structure of collagen is close to that of a fresh cornea.
Youvision Biotech Co., Ltd.

Dissolution and processing of cellulose

The invention relates to a method for dissolving the components of gel forming materials suitable for use in wound care comprising the steps of admixing said components with an ionic liquid. The ionic liquid may be selected from the group of tertiary amine n-oxides, n,n-dimethyl formamide/nitrogen tetroxide mixtures, dimethyl sulphoxide/paraformaldehyde mixtures and solutions of limium chloride in n,n-dimethyl acetamide or n-methyl pyrrolidone..
Convatec Technologies Inc.

Dimethylbenzoic acid compounds

The present invention provides a compound of the formula i: wherein a is: and w, y, x, r1, r2, r3, and r4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the ep4 receptor.. .
Eli Lilly And Company

Integrated process for converting methane to aromatics and other chemicals

Systems and methods for integrated production of aromatics and other chemicals are described. Systems and methods may include a process for producing benzene, methanol, butanals, dimethyl ethers, olefins and other chemicals that includes providing methane to a first reactor to produce a first product stream comprising benzene and hydrogen; recovering benzene and mixing the first product stream with a carbon dioxide and/or steam feed stream; providing the combined benzene depleted first product stream and carbon dioxide and/or steam feed stream to a second reactor to produce a second product stream comprising synthesis gas, water and unconverted methane and carbon dioxide; and providing the synthesis gas to a third reactor to produce a third product stream comprising methanol, butanals, and other chemicals..
Saudi Basic Industries Corporation

Cement products and methods of making and using the same

Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component.
Pioneer Surgical Technology, Inc.

Cerclage pessary containing progesterone of prolonged, sustained, and continuous release useful for prevention of preterm birth

Cerclage pessary containing progesterone homogeneously distributed in the pessary body providing a prolonged, sustained and continuous release for a period of at least 6 months, wherein the pessary consists of dimethylsiloxane elastomer with rtv (room temperature vulcanization) mechanism, the progesterone amount is from 20% to 30% w/w, relative to pessary weight and the ratios of the polymers forming the matrix is from 6:1 to 14 1. The cerclage pessary is useful for the prevention of preterm birth.
Laboratorios Andromaco S.a.

Tincture for infusing flavonoids and methods of use

Methods and formulations for infusing bioavailable flavonoid tinctures into food, beverage, cosmetic or drug products with minimal or no effect on the alcohol by volume of the product is provided. A flavonoid tincture includes an amount of trans-resveratrol, pterostilbene, quercetin, or combinations thereof, mixed with a solvent of pure, or majority by weight, ethanol or dimethyl sulfoxide the tincture is added to various food and beverages to make a bioavailable amount of flavonoids to be absorbed and metabolized by the body providing demonstrated health benefits..
Heart Healthy Spirits, Llc

Homogenous immunoassay with compensation for background signal

Homogeneous immunoassays that allow for compensation of background signals inherent in samples and reagents. The use of homogeneous immunoassays for the detection of the presence or amount of symmetrical dimethyl arginine (sdma) in biological samples.
Idexx Laboratories, Inc.

Ah-7921 detection

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-n-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4,-dichloro-n-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.. .
Randox Laboratories Ltd.

Removing resin coatings from surfaces

Methods and compositions are provided for removing a residue of resin from the surface of equipment. In one embodiment, the methods comprise: providing a cleaning solution comprising a ph-adjusting agent, a chemical solvent, and water, wherein the chemical solvent is selected from the group consisting of β-lactam, γ-lactam, δ-lactam, ε-lactam, 2-pyrrolidone, n-methylpyrrolidone, 1,3-dimethyl-2-imidazolidinone (dmi), caprolactam, cyclohexanone, cyclopentanone, β-butyrolactone, γ-butyrolactone, δ-decalactone, γ-valerolactone, ε-caprolactone, butylene carbonate, propylene carbonate, and ethylene carbonate, any combination thereof, and any derivative thereof; allowing the cleaning solution to contact a surface at least partially coated with a layer of resin; and allowing the cleaning solution to at least partially dissolve the resin..
Halliburton Energy Services, Inc.

Crystals of dispiropyrrolidine derivatives

Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of mdm2 are provided. The present invention provides crystals of (3′r,4′s,5′r)-n-[(3r,6s)-6-carbamoyltetrahydro-2h-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a salt thereof which inhibits mdm2 and has anti-tumor activity.
Daiichi Sankyo Company, Limited

Combination of braf and vegf inhibitors

A novel combination comprising the vegfr inhibitor 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, with a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of vegfr and/or b-raf is beneficial.. .
Novartis Ag

Treatment of obesity using non-daily administration of 6-o-(4-dimethylaminoethoxy) cinnamoyl fumagillol

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of, e.g., a metap-2 inhibitor.. .
Zafgen, Inc.

Compositions with a beef flavour and production thereof

The present invention provides a process for the production of a boiled beef flavour comprising heating a composition comprising a reducing sugar and cysteine and 4-hydroxy-2,5-dimethyl-3(2h)-furanone characterized in that the composition is heated and extruded in an extruder at a temperature between 80° c. And 140° c..
Dsm Ip Assets B.v.

Polyester composition for extrusion blow molded containers with improved aging and drop performance

The present invention relates to a polyester resin for extrusion blow molded containers comprising a branched copolymer and fumed silica to improve the aged drop performance said branched copolyester is made from the reaction of purified terephthalic acid or its dimethyl ester, ethylene glycol, bifunctional diacid other than terephthalic acid, diol other than ethylene glycol, and multifunctional compound having a least 3 carboxyl groups, hydroxyl groups and/or ester forming groups thereof, said fumed silica has a particle size of 0.1 to 5 microns and is present at about 100 ppm to about 2,500 ppm based on the weight of said copolyester.. .
Auriga Polymers, Inc.

Hydrochloride salt form for ezh2 inhibition

Provided herein are novel solid forms of n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.. .
Eisai R&d Management Co., Ltd.

Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists

The present invention relates to compounds of formula (i), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where r1 and r2 are, independently, hydrogen, halogen, c1_3 alkyl or c1-3alkoxy; r3 is phenyl optionally substituted by r4 and r5 which are, independently hydrogen, halogen, c1-3 alkyl, c1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, n,n-dic1-3alkyl-amide, carboc1-3 alkoxy or c1-3alkylsulphone groups; r3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.. .
Polfarmex S.a.

Method for separating n,n,n'-trimethylbisaminoethylether and/or n,n-dimethylbisaminoethylether from a mixture

(b2) separating the amide of n,n-dimethylbisaminoethylether from mixture b; and (c2) recovering n,n-dimethylbisaminoethylether from its amide by means of a transamidation reaction.. .

Process for preparation of dimethyl fumarate

The present invention relates to a process for the preparation of dimethyl fumarate, a compound of formula i, in a purity of at least 99.0% as determined by hplc, containing less than 400 ppm of an anion of a mineral acid and less than 5 ppm of dimethyl maleate.. .
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited

Electrospinning with reduced current or using fluid of reduced conductivity

A method comprises: dissolving an aromatic side chain polymer in a terpene, terpenoid, or aromatic solvent; dissolving an inorganic salt in a polar organic solvent; mixing the salt solution and the polymer solution; and using a predominantly terpene, terpenoid, or aromatic solvent phase of the mixture as electrospinning fluid. The fluid is electrospun from spinning tip(s) onto a target substrate.
Nanostatics Corporation

Immobilized metathesis tungsten oxo alkylidene catalysts and use thereof in olefin metathesis

Method of making an immobilized tungsten catalyst comprising or consisting of (≡sio)xw(═o)(═cr1r2)(r3 or r4)2-x(l)z, comprising at least the following step (i): (i) reacting silica (si02) with a tungsten oxo alkylidene complex comprising or consisting of (r3)(r4)w(═o)(═cr1r2)(l)y, preferably wherein ═cr1r2 is selected from ═chc(ch3)3 or ═ch(c(ch3)2)c6h5 and r3 and r4 are independently selected from pyrrol-1-yl, 2,5-dimethylpyrrol-1-yl, or 2,5-diphenylpyrrol-1-yl, or —or, wherein r is a six membered or 10 membered aryl ring, optionally substituted.. .
Ximo Ag

Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid

Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin d analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(s)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(s)-2-methylene-1α,25-dihydroxyvitamin d3, 2-methylene-1α,25-dihydroxy-(17e)-17(20)-dehydro-19-nor-vitamin d3, 2-methylene-19-nor-(24r)-1α,25-dihydroxyvitamin d2, 2-methylene-(20r,25s)-19,26-dinor-1α,25-dihydroxyvitamin d3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20r)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20s)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20s)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20s)-1α-hydroxyvitamin d3, 2-methylene-18,19-dinor-(20s)-1α,25-dihydroxyvitamin d3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof.
Wisconsin Alumni Research Foundation

4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of aki (acute kidney injury). Medicament and pharmaceutical composition thereof..

Enzalutamide in combination with afuresertib for the treatment of cancer

A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt thereof, and an akt inhibiting compound, for example: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or akt inhibition is beneficial, e.g., cancer.. .
Novartis Ag

Electrolyte solution for redox flow battery and redox flow battery comprising same

The provided are an electrolyte for redox flow battery and a redox flow battery comprising the same, wherein the electrolyte for redox flow battery comprises a solute and a solvent, wherein said solute comprises at least one of anode active material and cathode active material, wherein said anode active material comprises at least one of organic compounds having a carbonyl group such as benzophenone-, benzoquinone-, dimethyl terephthalate-, and 1,4-diacetylbenzene-based organic compounds, and said cathode active material comprises at least one of amine-, tetrathiafulvalene-, and n,n,n′,n′-tetramethyl-p-phenylenediamine-based organic compounds.. .
Seoul National University R&db Foundation

Iridium complexes and organic electroluminescence device using the same

The present invention discloses an iridium complexes and the organic el device employing the iridium complexes as light emitting guest of emitting layer can display good performance like as lower driving voltage and power consumption, increasing efficiency and half-life time. Additional, the present invention provide the suitable emitting host (h1 to h6) to collocate with the energy level of iridium complexes for the present invention.
Luminescence Technology Corporation

Methods and materials to enhance high temperature rheology in invert emulsions

An invert emulsion drilling fluid, and a method of drilling with such fluid, having improved rheology at low mud weights and high temperatures. The improved rheology is effected with addition of a rheology additive of the invention comprising fatty dimer diamines or dimer diamines and an organic acid or ester of the acid.
Halliburton Energy Services, Inc.

Floor coating compositions containing supramolecular polymers

The present invention provides an aqueous floor coating composition comprising: (a) water; (b) at least one supramolecular polymer; and (c) optionally, one or more additional ingredients. The supramolecular polymer (b) comprises polymerized units derived from: (1) one or more 4h monomers which comprise a polymerizable group and a quadruple hydrogen bonding (4h) moiety; (2) at least one monomer having acid functional groups; and (3) one or more ethylenically unsaturated monomers.
Rohm And Haas Company

Process for the preparation of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide

The invention relates to an improved process for synthesizing n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (i) compound (i) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.. .
Bristol-myers Squibb Company

Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor

An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. And having superior flt3 inhibitory activity.
Fujifilm Corporation

Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

The present invention relates to solid state forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1), pharmaceutical compositions thereof and methods therewith.. .
Vertex Pharmaceuticals Incorporated

Method for extraction and concentration of alkaloids using dimethyl ether

The present invention is directed to a method for the extraction and/or enrichment of alkaloids from a mixture containing such compounds. More particularly, the present invention is directed to methods for extracting one or more alkaloids using dimethyl ether..
Noramco, Inc.

Minocycline compounds and methods of use thereof

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of mssa, mrsa, b-streptococci, viridans streptococci, enterococcus, or combinations thereof..
Paratek Pharmaceuticals, Inc.

Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.. .
Takeda Pharmaceuticals U.s.a., Inc.

An anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells

The present invention provides the compound ormeloxifene [3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy)phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like c/ebpα and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (gcsfr).
Council Of Scienticfic & Industrial Research

Methods for the synthesis of tiotropium bromide

Present invention relates to methods for preparing (1α, 2β, 4β, 5α, 7β)-7-[(hydroxidi-2-thienllacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[,4]nonane-bromide.. .

Process for the preparation of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

The present invention relates to a process for the preparation of (1r,2r)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.. .
GrÜnenthal Gmbh

Oxygen enrichment membrane and producing same

Provided is an oxygen enrichment membrane that has both good oxygen separation performance and good membrane physical properties (mechanical strength, ease of membrane formation, etc.), and moreover, can be used to industrially obtain a high concentration of oxygen, and a method for producing the oxygen enrichment membrane. The oxygen enrichment membrane includes, as a main component, a hydrocarbon group-containing polysiloxane network structure material which is a reaction product of a tetraalkoxysilane and a hydrocarbon group-containing dialkoxysilane.
Toyo Tire & Rubber Co., Ltd.

Pharmaceutical compositions of growth hormone secretagogue receptor ligands

The present invention relates to improvements in compositions containing peptides that are ligands of the ghs receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of h-inp-d-bal-d-trp-phe-apc-nh2, which is a ligand of the ghs receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological ph that is slowly dissolved and released into the body fluid and bloodstream.
Ipsen Pharma S.a.s.

Novel crystal form of an organic compound and process for the preparation thereof

The present invention relates to novel crystalline form ii of 17α-acetoxy-21-methoxy-11β-[4-n,n-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as cdb-4124), processes for the preparation thereof and pharmaceutical composition comprising it. Form ii can be crystallized from different medium such as esters of c1-c4 alcohols and carboxylic acids, ketones, cyclohexane, acetonitrile, dimethylformamide, dimethyl sulfoxide, water and any mixture thereof..
Richter Gedeon Nyrt.

Losmapimod for use in treating glomerular disease

The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-n-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.. .
Glaxosmithkline Intellectual Property (no.2) Limited

Abuse-proofed oral dosage form

The present invention relates to an abuse-proofed oral dosage form with controlled release of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (a), at least one synthetic or natural polymer (c), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (b) and optionally a wax (d), component (c) or (d) in each case exhibiting a breaking strength of at least 500 n, preferably of at least 1000 n.. .
GrÜnenthal Gmbh

Multi-part kit system for the preparation of a disinfectant

A multi-part kit system comprising (i) a solid part a which comprises 10 to 80 wt. % of peroxy compound selected from the group consisting of khso5, k2s2o8, na2s2o8, magnesium monoperoxyphthalate hexahydrate, sodium percarbonate and sodium perborate, 0.1 to 10 wt.
The Chemours Company Fc, Llc

Method and cryopreservation of blood cells in a sterile environment

An apparatus and related method for the optimization of the cryopreservation of various types of cells, including but not limited to hematopoietic and mesenchymal stem and progenitor cells, and endothelial progenitor cells found in normal blood, placental/cord blood, bone marrow or the stromal vascular fraction of adipose tissue. The apparatus for cryopreservation of biological materials in a sterile environment comprises a cryopreservation workstation, a rigid disposable cartridge, and a freezing bag assembly.
Syngen, Inc.

Rubbery polysiloxanes carrying cyanoacrylate functions and related methods for their preparation and uses therefor

A family of silicone rubbers (e.g., polydimethylsiloxane) carrying one or more cyanoacrylate groups and their methods of production are provided. These silicone rubbers endowed with cyanoacrylate groups are useful in a variety of wound care applications, including wound closures, adhesives, sealants and skin protectors.
The University Of Akron

Method of producing pyrazino[2,1-c][1,2,4]triazine compound

A method of producing 4-(((6s,9s)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro -1h-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, including a step of adding a reaction mixture 1 containing (6s,9s)-n-benzyl-6-(4-hydroxybenzyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro -1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide, triethylamine and a solvent to a reaction mixture 2 containing a phosphorylating agent and a solvent.. .
Prism Pharma Co., Ltd.

Inhibitor of breast cancer resistance protein (bcrp)

Disclosed are compounds that inhibit breast cancer resistance protein (bcrp), of which compound (i-1), ((3s, 6s, 12as)-6-isobutyl-9-methoxy-3-methyl-2,3,6,7, 12, 12a- hexahydropyrazino[1′,2′: 1,6]pyrido[3,4-b]indole-1,4-dione) or a pharmaceutically acceptable salt thereof, and the compound 12, ((3s,6s,12as)-6-isobutyl-9-methoxy-3,10- dimethyl-2,3,6,7,12, 12a-hexahydropyrazino[1′,2′: 1,6]pyrido[3,4- b] indole-1,4-dione) or a pharmaceutically acceptable salt thereof. Also disclosed are methods of inhibiting bcrp or decreasing bcrp activity and methods of determining potential bcrp substrates..
Millennium Pharmaceuticals, Inc.

Method of producing silicone microspheres

A method of making silicone microspheres comprises nebulizing a silicone precursor solution comprising one or more oligomeric dimethylsiloxanes, a catalyst and a solvent into an aerosol comprising a plurality of droplets. Each droplet comprises the silicone precursor solution.
The Board Of Trustees Of The University Of Illinois

Radiation curable compositions for food packaging

An inkjet printing method includes the steps of jetting ink dots on a substrate of a plurality of radiation curable inkjet inks having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s−1, the plurality of radiation curable inkjet inks including a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of radiation curable inkjet ink; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group that the radiation curable composition further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate, a polymerizable co-initiator containing a tertiary amine and a polymeric co-initiator containing a tertiary amine; and (2) fully curing the jetted ink dots using one or more uv leds..
Agfa Graphics Nv

Improved process for the reductive amination and selective hydrogenation of substrates containing a selected halogen

Disclosed is a process for performing a chemical reaction selected from reductive amination and hydrogenation of a first functional group in an organic feed substrate, which feed substrate comprises at least one further functional group containing a halogen atom, wherein the halogen atom is selected from the list consisting of chlorine, bromine, iodine, and combinations thereof, in the presence of hydrogen and a heterogeneous catalyst comprising at least one metal from the list of pd, rh, and ru, together with at least a second metal from the list consisting of ag, ni, co, sn, cu and au. The process is preferably applied for the reductive amination of 2-chloro-benzaldehyde to form 2-chloro-benzyldimethylamine, as an intermediate in the production of agrochemically active compounds and microbiocides of the methoximinophenylglyoxylic ester series.
Taminco Bvba

Highly modified polyesters for containers

A polyester resin for use in a process in which, during an expansion step, an incompressible fluid is injected through an opening of a preform, formed of the polyester resin, to form a container. The polyester resin includes a crystallizable polyester polymer wherein the polyester polymer is comprised of acid moieties and glycol moieties, with at least 85% of the total moles of acid moieties being terephthalate derived from terephthalic acid or its dimethyl ester and at least 85% of the total moles of glycol moieties derived from ethylene glycol.
Discma Ag

Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.. .
Forward Pharma A/s

Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet..
Forward Pharma A/s

Dimethyl topics:
  • Physiologic
  • Hydrochloric Acid
  • Fresnel Zone
  • Aberration
  • Ophthalmic
  • Liquid Crystal
  • Imaging System
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Chloric Acid
  • Tartaric Acid
  • Fumaric Acid
  • Antagonist
  • Bradykinin
  • Enantiomer

  • Follow us on Twitter
    twitter icon@FreshPatents


    This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.



    2 - 1 - 104